A higher CD4+ and CD8+ T-cell proliferation rate was observed in PBMCs from aCD20-MS patients (%CD4+ CFSE-low, mean 3.9; %CD8+, 4.3) after incubation with a full spike peptide pool compared to healthy controls [%CD4+ CFSE-low, mean 1.3 (P<0.01); %CD8+, 0.4 (P<0.001)] (Figure 4B). The gene discussed is CD8A; the disease is myeloid sarcoma.